Search | Clinical Trials Finder

Conditions: Acute Respiratory Distress Syndrome
Interventions: N-acetyl cysteine; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Asthma
Interventions: fluticasone propionate, fluticasone propionate/salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Huntington Beach, California • Long Beach, California • Riverside, California + 16 more

Conditions: Mucociliary Clearance
Interventions: nebulized albuterol (2.5 mg/3ml/dose), nebulized levalbuterol (1.25 mg/3ml/dose), nebulized placebo (3ml/dose); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pediatric Asthma, Acute Asthma, BiPAP, Non-invasive Positive Pressure Ventilation
Interventions: Bilevel positive airway pressure ventilation; Device
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Persistent Asthma
Interventions: Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 33
States / cities: Birmingham, Alabama • Fairhope, Alabama • Glendale, Arizona + 30 more

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol, Fluticasone Propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 50
States / cities: Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more

Conditions: Muscular Dystrophies
Interventions: Albuterol, Oxandrolone; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 19
States / cities: Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more

Conditions: Asthma
Interventions: Levalbuterol tartrate MDI, racemic albuterol MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 45
States / cities: Montgomery, Alabama • Jonesboro, Arkansas • Corona, California + 39 more

Conditions: Asthma
Interventions: fluticasone propionate and salmeterol, budesonide and formoterol; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Bromide, Fluticasone Propionate/Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 35
States / cities: Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more

Conditions: Cystic Fibrosis, Healthy
Interventions: Albuterol, Placebo saline; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 15 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Asthma
Interventions: tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Segmental Bronchoprovocation with Allergen (SBP-Ag); Biological
Lead sponsor: Lu Yuan Lee; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Asthma
Interventions: fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Asthma
Interventions: Albuterol Sulfate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 44
States / cities: Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more

Conditions: Asthma in Children
Interventions: Bi-level Positive Airway Pressure, Sham Bi-level Positive Airway Pressure; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: Flovent Diskus, Home Environmental Intervention, Advair Diskus; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: Budesonide, albuterol, Ipratropium bromide, Prednisone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: East Meadow, New York • Queens, New York • The Bronx, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 15
States / cities: San Diego, California • Denver, Colorado • Wheat Ridge, Colorado + 12 more

Search by objective public record fields.

N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

Airway Temperature

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

Environmental Control as Add-on Therapy in Childhood Asthma

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

A Crossover Study in the Treatment of Patients With COPD